Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) insider Jones W. Bryan acquired 4,700 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were bought at an average cost of $10.60 per share, with a total value of $49,820.00. Following the transaction, the insider now directly owns 4,700 shares of the company’s stock, valued at approximately $49,820. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) traded up 0.48% on Monday, reaching $10.45. 465,408 shares of the company traded hands. The stock has a 50-day moving average price of $10.58 and a 200-day moving average price of $10.73. Sucampo Pharmaceuticals, Inc. has a 52-week low of $9.30 and a 52-week high of $17.55. The firm’s market cap is $482.73 million.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The business had revenue of $59.90 million during the quarter, compared to analysts’ expectations of $56.44 million. During the same quarter in the previous year, the company earned $0.24 EPS. The business’s revenue was up 15.3% on a year-over-year basis. Analysts anticipate that Sucampo Pharmaceuticals, Inc. will post $1.02 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Insider Buys $49,820.00 in Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/07/sucampo-pharmaceuticals-inc-scmp-insider-buys-49820-00-in-stock.html.

Several research analysts recently issued reports on the stock. BidaskClub lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Roth Capital set a $30.00 price target on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday. TheStreet lowered shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Maxim Group set a $23.00 price target on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Finally, Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $17.63.

Institutional investors have recently modified their holdings of the stock. Louisiana State Employees Retirement System boosted its position in shares of Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 100 shares during the last quarter. First Citizens Bank & Trust Co. purchased a new position in shares of Sucampo Pharmaceuticals during the second quarter valued at approximately $116,000. Karp Capital Management Corp purchased a new position in shares of Sucampo Pharmaceuticals during the first quarter valued at approximately $119,000. SG Americas Securities LLC boosted its position in shares of Sucampo Pharmaceuticals by 5.6% in the second quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 631 shares during the last quarter. Finally, Capstone Asset Management Co. boosted its position in shares of Sucampo Pharmaceuticals by 2.1% in the second quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 260 shares during the last quarter. Institutional investors own 58.20% of the company’s stock.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.